| |
| |
|
| Insider
Information: |
Henderson Michael Thomas |
| Relationship: |
Officer, Director |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
1,763,698 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$81,326,553 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,763,698 |
|
|
| Total
Value |
$81,326,553 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bridgebio Pharma, Inc. |
BBIO |
Chief Business Officer |
2020-12-01 |
274,211 |
2019-07-01 |
0 |
Premium* |
|
|
Apogee Therapeutics, Inc. |
APGE |
Officer, Director |
2023-07-13 |
1,489,487 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
36 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APGE |
Apogee Therapeutics, Inc. |
Chief Executive OfficerOfficer |
• • – |
2023-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,404,304 |
|
- |
|
| APGE |
Apogee Therapeutics, Inc. |
Chief Executive OfficerOfficer |
• • – |
2023-07-13 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
1,489,487 |
|
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2019-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
173,767 |
173,767 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2019-07-01 |
4 |
B |
$17.00 |
$119,000 |
D/D |
7,000 |
180,767 |
2.74 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-01-02 |
4 |
AS |
$32.69 |
$120,286 |
D/D |
(3,617) |
178,620 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-01-03 |
4 |
AS |
$32.28 |
$11,575 |
D/D |
(358) |
178,262 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-02-03 |
4 |
AS |
$34.90 |
$138,729 |
D/D |
(3,975) |
174,287 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-03-02 |
4 |
AS |
$32.20 |
$128,965 |
D/D |
(3,975) |
170,312 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-04-01 |
4 |
AS |
$25.40 |
$69,629 |
D/D |
(2,585) |
167,727 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-05-01 |
4 |
AS |
$29.19 |
$75,653 |
D/D |
(2,585) |
165,142 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-05-04 |
4 |
AS |
$30.01 |
$39,613 |
D/D |
(1,320) |
163,822 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-05-05 |
4 |
AS |
$30.47 |
$44,493 |
D/D |
(1,460) |
162,362 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
83,541 |
245,903 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-05-26 |
4 |
OE |
$1.05 |
$19,283 |
D/D |
18,365 |
264,268 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-06-01 |
4 |
AS |
$29.26 |
$75,912 |
D/D |
(2,585) |
261,683 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-06-03 |
4 |
AS |
$30.04 |
$23,549 |
D/D |
(784) |
261,399 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-06-08 |
4 |
AS |
$30.00 |
$18,185 |
D/D |
(606) |
260,293 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-07-01 |
4 |
OE |
$0.16 |
$1,600 |
D/D |
10,000 |
270,293 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-07-01 |
4 |
AS |
$30.63 |
$309,701 |
D/D |
(10,000) |
260,293 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-08-03 |
4 |
OE |
$0.16 |
$1,600 |
D/D |
10,000 |
270,293 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-08-03 |
4 |
AS |
$27.28 |
$273,741 |
D/D |
(10,000) |
260,293 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-08-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,812 |
273,211 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-08-16 |
4 |
D |
$28.53 |
$155,774 |
D/D |
(5,460) |
267,751 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-09-01 |
4 |
OE |
$0.16 |
$1,600 |
D/D |
10,000 |
277,751 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
Chief Business Officer |
• – – |
2020-09-01 |
4 |
AS |
$27.89 |
$287,334 |
D/D |
(10,000) |
267,751 |
0 |
% |
|
36 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
